Follow The Filings

KOD Kodiak Sciences Inc.

Health Care, filed as KODIAK SCIENCES INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Sold by 1 manager in 2026 Q2

  • 1 Owner
  • Max 0.0%
  • $1.4M
  • 1 reduce

In 2026 Q2 Polen Capital Management trimmed Kodiak Sciences.

Who owns this now

Largest portfolio weights among holders, up to 0.0% (Polen Capital Management). Not free-float ownership.

  1. Polen Capital Management Reduce 0.01%

Who owns KOD

Sorted by value, long equity only, as of 2026 Q2.

History
Polen Capital Management 0.01% Reduce −14.2% 35,469 $1.4M History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by KOD's executives, directors and 10% owners in the last 12 months, from their Form 4s

All KOD insider trades
  • $217M bought by 1 insider
  • None no sales outside a trading plan
  • $2.2M sold by 1 insider under 10b5-1 plans
  1. Baker Bros. Advisors LP Director, +5 joint filers
    Buy
    $63.4M 715,592 shares at $88.59 +3.7% to stake
    Traded Sep 28–29 Filed Sep 30
    ↗
  2. Baker Bros. Advisors LP Director, +5 joint filers
    Buy
    $35M 418,323 shares at $83.58 +2.2% to stake
    Traded Sep 28 Filed Sep 30
    ↗
  3. Baker Bros. Advisors LP Director, +5 joint filers
    Buy
    $58.6M 807,840 shares at $72.57 +4.4% to stake
    Traded Sep 28 Filed Sep 30
    ↗
  4. John A. Borgeson CFO
    Planned sale
    $1M 30,000 shares at $34.10 12% of stake
    Traded Jun 4 Filed Jun 5
    ↗
  5. John A. Borgeson CFO
    Planned sale
    $1.2M 30,000 shares at $39.92 14% of stake
    Traded Apr 2 Filed Apr 2
    ↗
  6. Baker Bros. Advisors LP Director, +5 joint filers
    Buy
    $60M 2,608,696 shares at $23.00 +17% to stake
    Traded Dec 18, 2025 Filed Dec 19, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 7 option exercises.

SEC filings

Recent issuer filings from EDGAR, 22 shown.

Filed Form Detail Links
SCHEDULE 13D/A — Filing Doc
8-K 8.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 5.07 Filing Doc
SCHEDULE 13G — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G — Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G — Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc
8-K 8.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13D/A — Filing Doc
8-K 8.01,9.01 Filing Doc
424B5 Filing Doc
424B5 Filing Doc

Source: SEC EDGAR submissions, updated 5 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Net income -$260.49M -$176.21M -$229.97M

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $289.31M $171.94M $214.82M
Total non-current assets * $190.06M $163.64M $136.72M
Total assets $479.37M $335.58M $351.53M
Total current liabilities $41.73M $25.57M $45.53M
Total non-current liabilities * $171.86M $159.72M $148.62M
Total equity $265.78M $150.29M $157.38M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$154.18M -$117.32M -$136.01M
Cash from investing $249.23M -$0.755M -$0.506M
Cash from financing $0.031M $0.501M $178.3M
Net change in cash * $95.07M -$117.57M $41.79M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.